Friday, August 21, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Rush to Establish Content-Authenticity Standards Amid Leadership Shakeups and Sustained Capex
Within days of each other in mid-August 2026, Google, Anthropic, and Spotify moved to formalize AI content watermarking and labeling policies, signaling an industry-wide push toward self-governed provenance standards as generative AI output floods consumer platforms. The shift coincides with executive turnover at OpenAI (Brad Lightcap's departure) and Meta's public AI manifesto, all set against continued heavy AI infrastructure capital expenditure and finance-sector moves (e.g., Wall Street paying for algorithmic edges on social signals) that underscore AI's deepening entanglement with capital markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,977
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,977 facts checked against source5,242 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 27, 2026

Pharma Conference Coverage Services: Real-Time Pharma Intelligence to Power Strategic Decision-Making

View original at finance.yahoo.com
Pharma Conference Coverage Services: Real-Time Pharma Intelligence to Power Strategic Decision-Making DelveInsight provides structured pharma conference coverage solutions designed to help industry leaders to track and interpret critical developments emerging from major healthcare conferences…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • DelveInsight is a leading provider of strategic conference coverage solutions, specializing in tracking, analyzing, and summarizing insights from global healthcare and pharmaceutical events across multiple therapy areas

    80% confidence

  • DelveInsight is a pioneer in providing customized conference coverage services, supporting client needs across indication and therapy area monitoring, inhibitor-specific updates, booth intelligence, KOL insights, phase transitions, and post-conference summaries

    80% confidence

  • The pharmaceutical sector continues to evolve at an unprecedented pace, and missing a pivotal presentation could mean missing emerging efficacy trends, novel mechanisms, or competitor signals shaping tomorrow's market

    80% confidence

  • Clients can track multiple conferences throughout the year under a single therapeutic area, such as Oncology, ensuring continuous year-round competitive and scientific intelligence

    80% confidence

  • DelveInsight's competitive intelligence services equip clients with real-time, accurate insights spanning multiple therapeutic domains including competitor pipelines, clinical trial tracking, gene and cell therapy innovations, market-entry strategies, and regulatory and patent landscapes

    80% confidence

  • In the rare disease space, DelveInsight monitors global R&D progress, competitive developments, and shifting regulatory landscapes to provide tailored insights that guide product positioning and investment strategies

    80% confidence

  • DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences

    80% confidence

  • DelveInsight's conference coverage spans major therapeutic areas from oncology to rare disease, annually covering major conferences such as ASCO, ESMO, ASH, AACR, ATS, ERS, etc.

    80% confidence

Cited in these Via News reports